Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26073271 | 1.00 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2ESR2ESR1 | |
| SCHEMBL29372292 | 0.96 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2ESR2ESR1 | |
| SCHEMBL3304298 | 0.91 | CA1 (0.44) | TAS1R3TAS1R1TAS1R2ESR2ESR1 | |
| SCHEMBL21791269 | 0.87 | MEN1 (0.39) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL16809810 | 0.87 | KMT2A (0.44) | TAS1R3TAS1R1TAS1R2TRPV1MEN1 | |
| SCHEMBL2804784 | 0.86 | TRPV1 (0.50) | TAS1R3TAS1R1TAS1R2ESR2TRPV1 | |
| SCHEMBL21183420 | 0.84 | LMNA (0.51) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL13936477 | 0.83 | ALDH1A1 (0.44) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL1725049 | 0.83 | ALDH1A1 (0.44) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL1725050 | 0.83 | ALDH1A1 (0.44) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | TAS1R3 4023/4885TAS1R1 3739/4885TAS1R2 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.